TEMENOS
Temenos (SIX: TEMN), the banking software company, today announced that registration is open for Temenos SCALE on the 17-18 November 2020. Temenos SCALE is the biggest developer conference in the banking industry, attracting developers from over 106 countries and from every type and size of institution across the banking industry. At Temenos SCALE, this global developer community will experience hands-on workshops, presentations and demonstrations with a focus on Explainable AI, microservices and open APIs and cloud technologies. Register here for this free to attend event.
Paul Roberts, Director, Temenos Developer Community & MarketPlace, Temenos, said: “Developers love Temenos because we have the most advanced technology, the richest ecosystem and the largest customer base of the most ambitious and challenger banks. We recognize the vital role our developer community plays in shaping the future of banking and we are committed to developers’ success. We invest an industry leading 20 per cent of our revenues into research and development – a further $1bn investment over just the next few years. And we are making significant investment in our developers too, supporting them with the tools, skills and knowledge to use our technology to solve real world problems at scale. Our API-first technology and modern microservices-based architecture enables rapid innovation and our MarketPlace gives developers a shop window into banks serving more than one billion people around the world. Banking truly is the most exciting space for developers right now and Temenos SCALE is the flagship event to bring the developer community together, to learn, share and grow.”
Attendees of Temenos SCALE will hear from influential technology and banking industry leaders. Temenos CEO Max Chuard will keynote on why now is a pivotal moment in the banking industry, how developers are shaping the future and making banking a force for good and how Temenos is supporting them with innovative technologies to create and bring new products to market faster.
Banks face mounting pressure as they try to keep pace with evolving customer expectations, competition and changing regulations. Covid-19 has accelerated the shift to digital banking and SaaS; Open Banking regulation is splitting the value chain and proving a catalyst for innovation; and with the rise of big tech, customers now expect seamless, hyper-personalized experiences. These trends are driven and enabled by technology and banks increasingly need developers to help them survive and thrive in this digital-first era.
The Temenos SCALE event will include over 40 sessions, including hands-on workshops and product demonstrations. Attendees will also hear from Temenos’ technology partners and customers. ABN AMRO will share insights on the power of analytics, Openbank on the extensibility of Temenos Transact to differentiate and Canadian Western Bank on design thinking. The event is supported by IBM as the headline sponsor, Microsoft, Red Hat, TailWind, NuoDB and Syncordis,
Andre Tost, Distinguished Engineer and CTO, IBM Cloud Pak Architecture, said: “At Temenos SCALE, you’ll hear about how IBM and our business partner Temenos are working together to bring hybrid cloud solutions to banking, and deliver greater automation, innovation and integration capabilities to our joint clients. I hope you’ll join us as we explore the incredible advances of modern software and API-led technology built with IBM offerings, like LinuxONE and IBM Cloud Paks. We look forward to engaging the brightest minds in the developer community – today’s change leaders – to discuss how we can work together to create powerful change in the banking industry on a global scale.”
Follow #TemenosSCALE on social media for live updates on LinkedIn, Twitter, Facebook and Instagram.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom